This is a recording for a LIVE webinar presented by Shazia Bano, PhD, Research Fellow from the Wellman Center for Photomedicine, Harvard Medical School Massachusetts General Hospital.
This webinar summarizes work that deals with:
1) The challenge and complexity of accurate evaluation of targeted nano-constructor
2) The engagement with the tumor receptor in vivo
3) Builds a concept for a non-invasive nano-tracer imaging approach which is reporting on the differential tumor kinetics of targeted nanomedicine
· Theranostic approach with validated tumor delivery of targeted nano-medicine using photoacoustic imaging (using the Vevo system)
· Quantifying direct in vivo molecular specificity for the targeted nano-medicines was performed by correlating potential measurements that were derived from the molecular images and then calculating in vivo concentration of the receptor EGFR (epidermal growth factor receptor) in 3D.
· Ligand-targeted nano-medicines are capable of quantifying the true molecular specificity in vivo.
· The misinterpretation of tumor to normal matrix can be avoided by this approach.
· Concept can be expanded to quantify the molecular specificity of any targeted nano-therapeutics or for any receptor target in the tumor.
· This non-invasive nano-tracer imaging approach can improve the sensitivity and the specificity over the conventional fluorescence imaging applications. This can specifically help in fluorescence guided surgery and directly approximate the receptor status of the tumor and provide valuable information for the choice of the therapies after surgery.
· The initial multi-color platform can be developed into a theranostic solution.
· Further studies will encapsulate multiple treatment modalities that exhibit known non-overlapping modes of cytotoxicity for the complex heterogeneous in vivo tumors.